Reach Us +44-1904-929220
Plasma IGF-1-molecular Stratification Of Hepatocellular Carcinoma Patients | 3556

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Plasma IGF-1-molecular stratification of hepatocellular carcinoma patients

3rd International Conference on Biomarkers & Clinical Research

Ahmed O Kaseb

ScientificTracks Abstracts: J Mol Biomark Diagn

DOI: 10.4172/2155-9929.S1.009

Dawei Hong completed his PhD in computer science (1996) and MS in mathematics (1982). In 1996 he became a faculty member of Minnesota State University, and was tenured in 1999. In 2001 he joined Rutgers University. Hong is a founding member of Center of Computational and Integrative Biology at Rutgers University. He currently is the chair of Department of Computer Science at Rutgers-Camden. His major research interest is modeling and computer simulation of biological systems with stochastic differential equations and their numerical solutions.
Dr. Ahmed O Kaseb graduated in 1996 (MBBS) from Cairo University School of Medicine, Egypt. After graduation, Dr. Kaseb began working at the University of Michigan, Ann Arbor, as a research fellow focusing on oncogenic viruses and cancer biomarkers. Later, he joined the MD Anderson Cancer Center in Houston, Texas, as an assistant professor of GI Medical Oncology, to focus on hepatobiliary malignancies in July 2007. His primary research interest is identifying some of the key prognostic and predictive molecular biomarkers that underlie malignant development and progression of HCC. Dr. Kaseb is interested to develop more informative prognostic and predictive molecular staging systems for HCC, with priority efforts given to the identification and characterization of potential targets for therapeutic intervention.
Relevant Topics